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This special issue includes articles that are beginning to
use emerging new technologies to address mechanisms of
injury in stroke and that can potentially provide
biomarkers for those injuries. The new technologies have
become very powerful, and the best uses of each need to
be carefully considered and applied thoughtfully to the
clinical problems of stroke.
Though genetics has revolutionized many areas in
medicine, it has yet to provide new insights into the
pathogenesis of stroke. A number of genes have been
associated with cardiovascular disease, including important
ones for hypertension, atrial fibrillation, aortic aneurysms
and others. One is hopeful as suggested by Markus that
ongoing GWAS studies will provide new insights into the
pathogenesis of ischemic stroke, cerebral aneurysms, and
other cerebrovascular diseases; however, it seems likely
that stroke is a multi-factorial, polygenic disease which will
require precise clinical phenotyping to yield associated
genes that will challenge the need to obtain large numbers
of samples for each phenotype.
Phenotyping might be helped by clinical syndromic
classifications, but it might also be helped by using blood
biomarkers. One should consider each tissue source of a
biomarker since it is likely to give different information
depending upon the question asked. For example, Foerch
suggests that rapid release of glial GFAP and S100B may
provide a serum/plasma marker of intracerebral hemor-
rhage because of rapid astrocyte injury compared to
slower astrocyte injury with ischemic stroke. This is an
intriguing idea and one wonders whether hemorrhages
associated with hypertension and hemorrhages due to
amyloid angiopathy might be associated with different
biomarkers. Thus, a variety of proteins released from
astrocytes might provide ancillary or even better markers
as addressed in the Feener study that might be specific for
different diseases or mechanisms of injury. Thus, the cell
source as well as temporal course may be helpful in
understanding pathogenesis.
It is important to remember that astrocyte, neuronal,
microglial, oligodendrocyte, and brain endothelial proteins
can probably be detected in serum and could point to specific
cellular injury. This degree of sophistication will certainly
require state of the art proteomic approaches as addressed in
part by the Kennedy article. A novel aspect of protein
metabolism is addressed in the study of Ning and Lo who
examined the degradation patterns of proteins following
stroke treated or untreated with tissue plasminogen activator
(tPA). They find that the proteomic degradation pattern is
altered by tPA and thus points to a new field where a
potential therapeutic effect can be assessed using virtually
any biomarker including protein degradation. Protein
degradation is of particular interest not only for the actions
of tPA but also for MMP9 and other proteolytic enzymes that
might be released following a stroke or activated within the
blood during and following a stroke. This may be an
extremely promising biomarker approach and also suggests
that measuring downstream effects of possible treatments
might help provide surrogate measures of drug efficacy that
could then be correlated with clinical response.
The above idea is also strongly supported by the
Montaner study. They found that tPA-treated patients had
lower serum interleukin (IL)-6 and IL-8 levels compared to
non-tPA-treated patients, whereas there were no changes in
TNF-alpha or intercellular adhesion molecule (ICAM)-1.
They noted that the patients who improved and those who
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re-canalized had the lowest IL-6 levels. These are extremely
important findings since they show cytokine differences
related to a treatment and clinical outcome. Such measures
will help understand the effects of treatment and its
mechanism. The data are interpreted to mean that tPA
may decrease inflammation, but it could be that a smaller
infarct produced lesser inflammation. The source of the
IL-6 is of particular interest since it certainly is related to
inflammatory cells, but one also wonders whether ischemic
endothelium and brain might also account for the decrease
in IL-6 related to tPA, which should decrease endothelial
injury and decrease brain injury. Whatever the source, this
cytokine could prove to be a valuable biomarker not only
for tPA treatment but possibly others. This study also points
to the fact that cytokines, chemokines, proteins, and other
molecules measured in serum/plasma can come from one or
multiple sources: the brain (all cells therein); endothelial
cells; other organs including the liver, kidney, lung, GI
organs, and others; and can come from inflammatory cells
in the blood, platelets in blood and even the red blood cells.
Measured levels are affected by the rate of secretion and
uptake back into cells, rates of removal from the blood, and
proteolysis within blood as pointed out by Ming and Lo.
All of these factors, including the uncertain cellular sources
make the measurements difficult to interpret. The bottom
line is, however, if the findings are consistent, they can
always be used as a biomarker for injury and/or treatment
and/or mechanism.
The field of biomarkers has recently been expanded by
the availability of array technology to assess mRNA,
microRNAs, and other newly discovered RNA species.
Measurements of RNA, however, are unique among the
biomarkers since RNA biomarkers in blood almost certain-
ly only reflect the intracellular contribution from inflam-
matory cells (like neutrophils, monocytes, lymphocytes),
platelets (which is found in immature platelets), red blood
cells (also in immature red blood cells) and any other
circulating cells which could include progenitor cells
(for endothelium and other organs), tumor cells, and
possibly cells from various organs depending upon the
disease state. The preponderant RNA, however, is from
inflammatory cells, platelets, and red blood cells. This has
led our group to pioneer the measurement of RNA in
peripheral blood with the finding that panels of RNAs can
be shown to correlate with the occurrence of ischemic
stroke and the cause of ischemic stroke. This work has been
extended by Jeyaseelan in this special issue as well as by
others in the field like Vemuganti and colleagues who find
specific microRNAs induced in the brain or blood following
brain ischemia. The importance of these microRNAs is that
they must be expressed within cells in the blood and likely
play a role in RNA expression and protein synthesis by the
inflammatory and immature platelets in the blood and could
be useful biomarkers for specific mechanisms and possibly
treatment targets themselves.
Inflammation, inflammatory cells, and Toll-like receptors
(TLRs) are the topic of the Stenzel-Poore review. As pointed
out, modulating TLRs can acutely worsen or improve stroke.
In addition, pre-conditioning with TLR acting agents can
also protect the brain against stroke. These studies are very
important not only for the potential role of pre-conditioning
to protect against stroke prior to surgery or other anticipated
injury, but they also suggest that the status of TLRs before
stroke could be important in determining whether a stroke
will occur and how severe it might be. That is, TLR status
could be a biomarker for the risk of having a stroke, a field
unexplored in humans at least. Moreover, it is important to
know which TLRs on which cells are mediating acute injury
and pre-conditioning induced neuroprotection. If they are
mainly on the inflammatory cells, this again points to the
very important role of inflammation in potentially causing or
worsening ischemic stroke. As the anti-ICAM trial showed,
stimulating the immune system in humans unequivocally
worsens stroke in humans. It is still unclear whether
downregulating the immune system in humans with stroke
will improve outcomes and, if so, what would be the safest
and most likely method of immune system modulation to
work?
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